Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
67.75
+2.67 (4.10%)
At close: May 12, 2025, 4:00 PM
67.25
-0.50 (-0.74%)
After-hours: May 12, 2025, 6:56 PM EDT
Insmed Revenue
Insmed had revenue of $92.82M in the quarter ending March 31, 2025, with 22.94% growth. This brings the company's revenue in the last twelve months to $381.03M, up 20.77% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$381.03M
Revenue Growth
+20.77%
P/S Ratio
29.40
Revenue / Employee
$299,788
Employees
1,271
Market Cap
12.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INSM News
- 4 days ago - Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 13 days ago - Baron Health Care Fund Q1 2025 Top Contributors And Detractors - Seeking Alpha
- 13 days ago - Insmed To Present at the BofA Securities 2025 Health Care Conference - PRNewsWire
- 17 days ago - Insmed: Poised For Transformation Beyond ARIKAYCE - Seeking Alpha
- 18 days ago - Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 - PRNewsWire
- 19 days ago - New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis - PRNewsWire
- 19 days ago - Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 - PRNewsWire